Debate Intensifies Over Expanding Access to Testosterone Therapy
A recent expert panel convened by the US Food and Drug Administration (FDA) has sparked significant debate regarding the broader use of testosterone therapy. While currently approved for individuals with medically confirmed low hormone levels, panel members argued for expanding access, labeling testosterone replacement as a cornerstone of preventive health. Proponents, including Harvard urologist Abraham Morgentaler, suggest that even asymptomatic men with low testosterone should be treated to prevent illness. However, critics contend that lifestyle changes are sufficient for many, particularly young men without underlying medical issues. The trend is further fueled by popular media figures and specialized clinics marketing testosterone for energy and muscle building, despite its classification as a controlled substance due to abuse potential. Historical concerns linking testosterone to prostate cancer are being re-evaluated, with newer evidence suggesting these risks may have been overstated. Nevertheless, high-dose usage carries risks such as infertility and increased mortality. This article examines the conflicting clinical viewpoints, the growing commercialization of hormone therapy, and the evolving scientific understanding of its safety and benefits for both men and women.
Wire timeline
Debate Intensifies Over Expanding Access to Testosterone Therapy
A recent expert panel convened by the US Food and Drug Administration (FDA) has sparked significant debate regarding the broader use of testosterone therapy. While currently approved for individuals with medically confirmed low hormone levels, panel members argued for expanding access, labeling testosterone replacement as a cornerstone of preventive health. Proponents, including Harvard urologist Abraham Morgentaler, suggest that even asymptomatic men with low testosterone should be treated to prevent illness. However, critics contend that lifestyle changes are sufficient for many, particularly young men without underlying medical issues. The trend is further fueled by popular media figures and specialized clinics marketing testosterone for energy and muscle building, despite its classification as a controlled substance due to abuse potential. Historical concerns linking testosterone to prostate cancer are being re-evaluated, with newer evidence suggesting these risks may have been overstated. Nevertheless, high-dose usage carries risks such as infertility and increased mortality. This article examines the conflicting clinical viewpoints, the growing commercialization of hormone therapy, and the evolving scientific understanding of its safety and benefits for both men and women.
Nature